SUPX:NASDAQSuperX AI Technology Limited Analysis
Data as of 2026-05-03 - not real-time
$7.68
Latest Price
8/10Risk
Risk Level: High
Executive Summary
SuperX AI Technology Limited (SUPX) trades at $7.68, roughly 71% above its DCF‑derived fair value of $4.48, while the 20‑day SMA ($8.24) sits just above price and the 200‑day SMA ($28.27) remains far higher, underscoring a strong bearish bias. The RSI of 43.5 suggests neutral momentum, and the MACD line (-0.325) is marginally above its signal (-0.327) with a tiny bullish histogram, offering no clear short‑term reversal. Volatility is extreme at 137% over the past 30 days and beta is elevated at 1.36, indicating the stock moves aggressively with the market. Support at $6.61 and resistance at $11.93 frame a narrow trading range, with current price near the lower bound, hinting at limited upside in the near term.
Fundamentally, SUPX posted a 130% revenue surge but operates at a negative operating margin (-2.0%) and zero net profit, with negative ROE (-1.58%) and a high price‑to‑book of 8.59. Cash ($17.21M) comfortably exceeds debt ($1.76M) yet operating cash flow is negative, and free cash flow is modestly positive. Recent material news highlights progress on a share‑repurchase program, signaling management confidence, and a strategic AI innovation centre partnership in Singapore, which could improve top‑line growth but does not yet offset the deep profitability gaps.
Fundamentally, SUPX posted a 130% revenue surge but operates at a negative operating margin (-2.0%) and zero net profit, with negative ROE (-1.58%) and a high price‑to‑book of 8.59. Cash ($17.21M) comfortably exceeds debt ($1.76M) yet operating cash flow is negative, and free cash flow is modestly positive. Recent material news highlights progress on a share‑repurchase program, signaling management confidence, and a strategic AI innovation centre partnership in Singapore, which could improve top‑line growth but does not yet offset the deep profitability gaps.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near support with limited upside
- Neutral RSI and marginal bullish MACD signal
- Extreme short‑term volatility
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Current price far above DCF fair value
- Persistent negative operating margins and cash‑flow weakness
- High beta and sector‑specific tech risk
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Potential upside from AI innovation centre partnership
- Share‑repurchase program indicating management confidence
- Fundamental profitability challenges remain unresolved
Key Metrics & Analysis
Financial Health
Revenue Growth130.40%
ROE-158.36%
ROA-25.03%
Debt/Equity8.87
P/B Ratio8.6
Op. Cash Flow$-8334584
Free Cash Flow$4.9M
Industry P/E38.5
Technical Analysis
TrendBearish
RSI43.5
Support$6.61
Resistance$11.93
MA 20$8.24
MA 50$9.37
MA 200$28.27
MACDBullish
VolumeStable
Fear & Greed Index91.09
Valuation
Fair Value$4.48
GradeOvervalued
TypeBlend
Risk Assessment
Beta1.36
Volatility137.29%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.